Baiguoyuan Group (02411): Optimistic about the company's development prospects, several controlling shareholders have made voluntary sales ban commitments
[Important matters]
Baiguoyuan Group (02411): Optimistic about the company's development prospects, several controlling shareholders have made voluntary sales ban commitments
Shanghai Pharmaceutical (02607): Rabeprazole sodium enteric tablets passed generic drug consistency evaluation
China Biopharmaceutical (01177): Data from 6 studies on “anlotinib hydrochloride capsules”, “TQB2916 (CD40 agonist)”, and “FHND6091 (proteasome inhibitor)” were announced in 2024 AACR
[Financial Report Data]
361 degree (01361): Retail sales of main brand products achieved positive double-digit year-on-year growth in the first quarter
The cumulative contract sales volume of China Resources Land (01109) in the first quarter was about RMB 50.72 billion, a decrease of 35.8% year-on-year
Yuyuan Group (00551)'s consolidated cumulative net operating income of US$2.03 billion for the first three months decreased by 4.94% year-on-year
Longhu Group (00960) achieved a total contract sales amount of 23.48 billion yuan in the first 3 months
Yuexiu Real Estate (00123)'s cumulative contract sales for the first 3 months were about RMB 21.702 billion, down about 50.5% year on year
[Repurchase Cancellation]
Tencent Holdings (00700) spent HK$1,001 billion to buy back 3.2 million shares on April 10
Meituan-W (03690) spent about HK$400 million to buy back 3.8817 million shares on April 10
Changshi Group (01113) spent HK$245.28,600 to buy back 752,500 shares on April 10
For more details, please refer to Zhitong Financial Network ()